Loading...
Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof
The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib,...
Na minha lista:
| Udgivet i: | J Med Chem |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8327781/ https://ncbi.nlm.nih.gov/pubmed/33570945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c01952 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|